Early regression index-guided adaptive dose escalation in locally advanced rectal cancer: results of the prospective THUNDER-2 trial.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 42551632.
- Also identified by DOI 10.1016/j.radonc.2026.111719.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Complete response (CR) after neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC) is associated with improved outcomes and may enable organ-preserving strategies. The Early Regression Index (ERI) is an imaging biomarker developed to predict treatment response. THUNDER-2 trial investigated ERI-guided magnetic resonance imaging (MRI)-based adaptive dose escalation to improve CR rates in predicted non-responders. Patients with LARC underwent MRI-guided nCRT with concurrent capecitabine or 5-fluorouracil. ERI was calculated between simulation and the 10th treatment fraction. Patients with ERI ≤ 13.1 continued standard radiotherapy, whereas those with ERI > 13.1 received an adaptive boost to 60.1 Gy using online adaptive radiotherapy. CR was defined as pathological complete response (pCR) or sustained clinical complete response (cCR) at 2 years. Patients with cCR were considered for non-operative management with intensive follow-up. Sixty-two patients were enrolled (48.4% responders, 51.6% non-responders). Adaptive dose escalation increased the CR rate in non-responders from the historically expected value of approximately 3% to 21.9%, while maintaining acceptable toxicity. Responders achieved significantly higher TME (total mesorectal excision)-free survival than non-responders (38.7% vs 8.3%; hazard ratio (HR) 2.35, 95% confidence interval (CI) 1.29-4.26; p = 0.004). Two local regrowths occurred among non-responders and were successfully salvaged. ERI was the only variable significantly associated with CR in both univariate and multivariable analyses (adjusted odds ratio (OR) 0.912, 95% CI 0.840-0.990; p = 0.028). ERI-guided MRI-based adaptive dose escalation was feasible and associated with higher-than-expected CR rates in predicted non-responders, supporting personalized treatment intensification and organ-preservation strategies in LARC (THUNDER-2; NCT04815694).